Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Impedimed Limited ( (AU:IPD) ) has issued an announcement.
ImpediMed Limited reported a significant increase in US sales for Q4 FY25, achieving a record Total Contract Value of A$6.3 million. This growth, attributed to new leadership initiatives and strategic partnerships like the one with Legacy Health, has enabled the company to qualify for an additional US$5 million in funding from SWK Funding LLC. The funds will support ImpediMed’s growth and commercialization efforts, positioning the company for long-term success and shareholder value creation.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
ImpediMed Limited operates in the healthcare industry, focusing on digital health solutions. Its primary product, the SOZO® Digital Health Platform, is used for lymphoedema prevention and management, particularly in cancer survivorship programs. The company is committed to improving patient outcomes and has a strong market focus on healthcare providers and institutions.
Average Trading Volume: 2,401,535
Technical Sentiment Signal: Sell
Current Market Cap: A$70.96M
See more insights into IPD stock on TipRanks’ Stock Analysis page.